Literature DB >> 8102248

Critical role of interleukin-2 in the development of acute graft-versus-host disease.

C S Via1, F D Finkelman.   

Abstract

Prior work using the parent-into-F1 model of graft-versus-host disease (GVHD) has shown that production of IL-2 by donor CD4+ T cells is an early, initiating event in either acute or stimulatory forms of GVHD. The aim of the present study was to determine whether acute GVHD could be prevented by blocking the effects of IL-2 in vivo during the first 2 weeks of disease. Acute GVHD was induced in B6D2F1 mice by the injection of C57BL/6 spleen cells i.v. Mice were untreated or received either anti-IL-2 mAb (S4B6) or control mAb at the time of GVHD induction and 1 week later. At 2 weeks, untreated or control mAb treated GVHD mice exhibited findings typical of acute GVHD, i.e. (i) in vitro donor anti-host cytotoxic T lymphocyte (CTL) activity, (ii) significant reductions in both numbers and function of splenic lymphocytes, and (iii) in vitro suppressor cell activity which profoundly blocked IL-2 production by normal syngeneic spleen cells. All of these findings were reversed or significantly inhibited in acute GVHD mice receiving anti-IL-2 treatment. Additionally, anti-IL-2 treated GVHD mice exhibited features previously observed in stimulatory GVHD such as: (i) B cell hyperactivity, (ii) a mild defect in CD4+ T cell production of IL-2 in vitro, and (iii) the ability to induce in co-culture a similar CD4+ cell defect in normal, syngeneic F1 spleen cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102248     DOI: 10.1093/intimm/5.6.565

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  25 in total

1.  Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.

Authors:  Yamin Tan; Haowen Xiao; Depei Wu; Yi Luo; Jianping Lan; Qifa Liu; Kang Yu; Jimin Shi; Jingsong He; Weiyan Zheng; Xiaoyu Lai; Yuanyuan Zhu; Kaili Du; Yishan Ye; Yanmin Zhao; Gaofeng Zheng; Yongxian Hu; Xiaoyan Han; Yanlong Zheng; Guoqing Wei; Zhen Cai; He Huang
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

Review 2.  Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE.

Authors:  I Puliaeva; R Puliaev; C S Via
Journal:  Autoimmun Rev       Date:  2008-08-24       Impact factor: 9.754

3.  Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity.

Authors:  A Shustov; I Luzina; P Nguyen; J C Papadimitriou; B Handwerger; K B Elkon; C S Via
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

4.  In vivo IL-4 prevents allo-antigen driven CD8+ CTL development.

Authors:  Charles S Via; Kateryna Soloviova; Maksym Puliaiev; Roman Puliav; Irina Puliaeva; Suzanne C Morris; Fred D Finkelman
Journal:  Clin Immunol       Date:  2017-03-27       Impact factor: 3.969

5.  B cell depletion in murine lupus using cytotoxic T lymphocytes in vivo: Feasibility and benefit.

Authors:  Kateryna Soloviova; Irina Puliaeva; Maksym Puliaiev; Roman Puliaev; Charles S Via
Journal:  Cell Immunol       Date:  2020-05-05       Impact factor: 4.868

Review 6.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

Authors:  Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

8.  Roles of Host Nonhematopoietic Cells in Autoimmunity and Donor Cell Engraftment in Graft-versus-host Disease.

Authors:  Juyang Kim; Sohye Park; Hyun-A Kim; Daehee Jung; Hyun Ju Kim; Hye-Jeong Choi; Hong Rae Cho; Byungsuk Kwon
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

9.  Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation.

Authors:  Courtney M Lappas; Po-Ching Liu; Joel Linden; Elizabeth M Kang; Harry L Malech
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

10.  The Parent-into-F1 Model of Graft-vs-Host Disease as a Model of In Vivo T Cell Function and Immunomodulation.

Authors:  R A Puliaev; I A Puliaeva; A E Ryan; C S Via
Journal:  Curr Med Chem Immunol Endocr Metab Agents       Date:  2005-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.